«Which stent for which coarctation based on mechanical properties?» Modelisation
|
|
|
- Johnathan Potter
- 5 years ago
- Views:
Transcription
1 «Which stent for which coarctation based on mechanical properties?» Modelisation Patrice Guérin, Clément Mercier, Fabienne Jordanna L Institut du Thorax et Inserm U791 CHU Nantes JFCPC 2015
2 Déclaration de Relations Professionnelles Disclosure Statement of Financial Interest J'ai actuellement, ou j'ai eu au cours des deux dernières années, une affiliation ou des intérêts financiers ou intérêts de tout ordre avec une société commerciale ou je reçois une rémunération ou des redevances ou des octrois de recherche d'une société commerciale : I currently have, or have had over the last two years, an affiliation or financial interests or interests of any order with a company or I receive compensation or fees or research grants with a commercial company : Affiliation/Financial Relationship Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit Company Lilly AstraZeneca Actelion Abbott Vascular
3 The laboratory Bench test : Camera Binocular magnifying glass Microscanner In-vivo studies Rats Rabbits Pigs
4 3D reconstruction
5 In vivo analysis
6 Pigs : In vivo analysis (2)
7 Scanning electron microscopy (J28)
8 Aortic coarctation 8
9 Texture analyzer TA HD PLUS Measuring the force versus displacement Max Force ± 5kg ± 500kg Force Resolution 0.1g 10g Force Accuracy 0.025% 0.025% Texture Technology
10 Caliper Measuring range Resolution 0-150mm 0.01mm Fischer scientific 10
11 Analysed stents Modèle Laboratoire Composition Diamètre d'usage Longueur d'usage AndraStent XL ANDRAMED Cobalt-Chronium mm mm 1 n AndraStent XXL ANDRAMED Cobalt-Chronium mm mm 1 Valéo BARD Stainless steel 316L 9 mm NC 2 Covered CP stent 16 mm NuMED Platinium/Iridium (90/10) Covered CP stent 28 mm NuMED Platinium/Iridium (90/10) CP stent 55 mm NuMED Platinium/Iridium (90/10) mm 10,5-16,1 mm mm 19,1-26,2 mm mm NC 1 Palmaz CORDIS Stainless steel 316L mm 37,79-30,58 mm IntraStent Mega LD Stent Ev3 Stainless steel 316L 9-12 mm 26 mm 1 1 IntraStent Max LD Stent Ev3 Stainless steel 316L 12 mm 26 mm 2 IntraStent DoubleStrut LD Stent Ev3 Stainless steel 316L 9-12 mm 56 mm 1
12 Mechanical tests Recoil and foreshortening Averall compression Overall Radial Force Local compression Segmental Radial Force Longitudinal compression
13 Mechanical tests Recoil and foreshortening Averall compression Overall Radial Force Local compression Segmental Radial Force Longitudinal compression
14 Recoil et du Foreshortening Recoil : Diametrical reduction after balloon deflation Foreshortening : Longitudinal reduction between the initial and final state of the stent
15 Initial Recoil 7,00 % After first inflation at 18 mm Minus 1 mm after deflation in case of mm vessel 6,00 % 5,19 % 5,00 % 4,03 % 4,00 % 3,36 % 3,58 % 3,68 % 3,00 % 2,48 % 2,73 % 2,00 % 1,82 % 1,85 % 1,00 % 0,00 % Recoil initial
16 Mean Recoil 6,00 % 5,00 % 4,52 % 5,18 % Mean recoil after 3 deployement. 4,00 % 3,00 % 2,00 % 1,34 % 1,41 % 2,21 % 2,24 % 3,00 % 3,14 % 3,49 % 1,00 % 0,00 % Recoil moyen Mean Recoil < initial Recoil (except for Palmaz stent)
17 Foreshortening 50,00 % 45,00 % 45,18 % 40,00 % 35,00 % 30,00 % 25,00 % 20,00 % 15,00 % 10,00 % 5,00 % 6,06 % 9,92 % 13,76 % 14,15 % 14,40 % 14,92 % 16,06 % 18,52 % 0,00 % Foreshortening
18 Foreshortening 50,00 % 45,00 % 40,00 % 35,00 % 30,00 % 25,00 % 10% : Minus 0.5 cm in lenght for a mm stent! 15% : Minus 0.75 cm in lenght for a mm stent! 45,18 % 20,00 % 15,00 % 10,00 % 5,00 % 6,06 % 9,92 % 13,76 % 14,15 % 14,40 % 14,92 % 16,06 % 18,52 % 0,00 % Foreshortening
19 Foreshortening 50,00 % 45,00 % 40,00 % 35,00 % 30,00 % 25,00 % Valeo could be open until 18 mm but should it be (nominal diameter 6-10 mm) 45,18 % 20,00 % 15,00 % 10,00 % 5,00 % 6,06 % 9,92 % 13,76 % 14,15 % 14,40 % 14,92 % 16,06 % 18,52 % 0,00 % Foreshortening
20 Mechanical tests Recoil and foreshortening Averall compression Overall Radial Force Local compression Segmental Radial Force Longitudinal compression
21 Overall compression between two parallel plates Determination of the radial force to develop a diametrical reduction of 60% Stent structure Folding Axis
22 Overall compression between two parallel plates 1400,0 g 1200,0 g 1188,8 g 1000,0 g 996,1 g 908,200 g 800,0 g 600,0 g 694,3 g 667,1 g 586,9 g 558,7 g 538,2 g 460,7 g 400,0 g 200,0 g 0,0 g CP Stent 55mm Palmaz IntraStent DoubleStrut IntraStentMAX IntraStent MEGA CCP Stent 28mm AndraStent XXL Valéo AndraStent XL Force appliquée à 60% de réduction diamétrale There is a relationship between required force and stent s lenght
23 Overall compression between two parallel plates 40,00 35,00 30,00 31,96 30,58 30,16 29,50 28,45 27,61 25,00 25,22 25,12 22,89 20,00 15,00 15,27 10,00 5,00 0,00 Ratio Force/Lenght Low resistance of intrastent DoubleStrut Ratio (g/mm de stent) Ratio Force _ appliquée longueur_ stent
24 Overall compression between two parallel plates 40,00 35,00 30,00 31,96 30,58 30,16 29,50 28,45 27,61 25,00 25,22 25,12 22,89 20,00 15,00 15,27 10,00 5,00 0,00 Ratio Force/Lenght Low resistance of intrastent DoubleStrut Ratio (g/mm de stent) Ratio Force _ appliquée longueur_ stent
25 Overall compression between two parallel plates 40,00 35,00 30,00 31,96 30,58 30,16 29,50 28,45 27,61 25,00 25,22 25,12 22,89 20,00 15,00 15,27 10,00 5,00 0,00 Ratio Force/Lenght Low resistance of intrastent DoubleStrut Ratio (g/mm de stent) Ratio Force _ appliquée longueur_ stent
26 Overall compression between two parallel plates 40,00 35,00 30,00 31,96 30,58 30,16 29,50 28,45 27,61 25,00 25,22 25,12 22,89 20,00 15,00 15,27 10,00 5,00 0,00 Ratio Force/Lenght Low resistance of intrastent DoubleStrut Ratio (g/mm de stent) Ratio Force _ appliquée longueur_ stent
27 Determination of the radial force developed locally to 60% of diameter reduction. Local compression
28
29 Local compression Stents classification according to the cell resistance to the applied stress 600,0 g 528,3 g 500,0 g 446,1 g 445,0 g 400,0 g 300,0 g 338,0 g 337,5 g 319,4 g 317,7 g 279,1 g 200,0 g 219,1 g 201,4 g 100,0 g 0,0 g Force à 60% de réduction diamétrale 29
30 Longitudinal reduction of 50% of the original length Longitudinal Compression
31 Longitudinal Compression 3500,0 g 3000,0 g 2500,0 g 2000,0 g 2868,8 g E 2162,8 g 2117,9 g 1478,3 g E : elastic deformation of the stent E 1500,0 g 1304,8 g 1000,0 g 500,0 g 0,0 g 987,4 g E E 208,5 g 167,2 g E E 71,8 g 62,5 g Force enregistrée à 1 Palmaz, CCP Stent 16mm, CCP Stent 28, CP Stent 55mm : destructurations
32 Take home messages AndraStent XL : Important recoil and foreshorteningimportant but a good radial force : Short stenosis requiring a good radial force. Curves AndraStent XXL : Important recoil but low foreshortening and an excellent radial force : Recommended. Curves Valéo : Small recoil at 18 mm but very high foreshortening and as a consequence an excellent radial force : should we use it at 18 mm? CP ou CCP stent : Important recoil and foreshortening but a good radial force, intermediate recoil and radial force with important foreshortening (15%) «Classical lesion» without significant curve» Palmaz : The worst recoil, important foreshortening (10%), correct radial force «Classical lesion» without significant curve» IntraStent Mega and Max LD Stent : Low recoil, 13% foreshortening, good radial force «Classical lesion requiring a low recoil and good radial force» IntraStent DoubleStrut LD Stent : No recoil but the lower radial force :» «coarcation of the young in a curve»
33 AndraStent XL : Important recoil and important foreshortening but a good radial force : Short stenosis requiring a good radial force, curves.
34 Valéo : Small recoil at 18 mm but very high foreshortening and as a consequence an excellent radial force : should we use it at 18 mm?
35 CP ou CCP stent : Important recoil and foreshortening but a good radial force, intermediate recoil and radial force with important foreshortening (15%) «Classical lesion» without significant curve
36 Study limitations n=2 Ex vivo manipulations Ongoing study BVS Bench Testing Appearances are Sometimes Deceptive
37 Thank you for your attention
38 Bibliographie Analyseur de Texture TA.HD Plus Organisation internationale de normalisation. Implants cardiovasculaires Dispositifs endovasculaires Partie 2 : endoprothèses vasculaires. Genève: ISO, p. Norme internationale ISO :2013 Barragan P, Rieu R, Garitey V, Roquebert PO, Sainsous J, Silvestri M, Bayet G. Elastic recoil of coronary stent: A comparative analysis. Catheter Cardiovasc Interv ; 50(1): Choi H, Joo SM, Kim HK, Shin JH, Hwang MH, Choi J et al. A comparative reliability and performance study of different stent designs in terms of mechanical properties: foreshortening, recoil, radial force, and flexibility. Artif. Organs 2013;37(4): Ormiston J, Webber B, White J, Ubod B, Webster M. Point compression and stent longitudinal deformation: a novel clinically-relevant bench tests comparing 6 contemporary stent designs. EuroIntervention doi: /CIRCINTERVENTIONS Leibundgut G, Gick M, Toma A, Valina C, Löffelhardt N, Büttner HJ, Neumann F-J. Longitudinal compression of the platinum-chromium everolimus-eluting stent during coronary implantation: Predisposing mechanical properties, incidence, and predictors in a large patient cohort. Catheter Cardiovasc. Interv. 2013; 81(5):e Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the Proportional Neointimal Response to Coronary Artery Injury: Results in a Porcine Model. J Am Coll Cardiol ;19(2): Illustration coeur :
39 PKP (POT, Kissing, final POT) Absrorb Final result very similar to PSP Good result on Main branch Bench B Bench A
L essentiel de 2013 Exercice Readaptation et Sport (GERS) Dr Marie Christine Iliou
PARIS 15-19 Janvier 2014 L essentiel de 2013 Exercice Readaptation et Sport (GERS) Dr Marie Christine Iliou Déclaration de Relations Professionnelles Disclosure Statement of Financial Interest J'ai actuellement,
Paradoxical low flow-low gradient severe aortic stenosis: where are we?
Journées Européennes de la SFC Paris, 15 janvier 2016 Paradoxical low flow-low gradient severe aortic stenosis: where are we? Nicolas Mansencal Hôpital Ambroise Paré, Boulogne Centre de Réf ce pour les
Mitral valve apparatus in Hypertrophic Cardiomyopathy: a specific assessment?
Nancy, September 17th, 2015 Mitral valve apparatus in Hypertrophic Cardiomyopathy: a specific assessment? Inserm UMR1087 Institut du Thorax, Nantes Thierry le Tourneau Déclaration de Relations Professionnelles
Cardiac Rehabilitation and Electromyostimulation
CREMS-HF Cardiac Rehabilitation and Electromyostimulation Dr Marie Christine Iliou Dr Bénédicte Vergès CREMS-HF study GERS SFC Déclaration de Relations Professionnelles Disclosure Statement of Financial
Echocardiography of the young athlete: Where are the limits? 24 èmes Journées Européennes de la Société Française de cardiologie janvier 2014
Echocardiography of the young athlete: Where are the limits? 24 èmes Journées Européennes de la Société Française de cardiologie 15-18 janvier 2014 Sylvain GUERARD LYON-BRON Déclaration de Relations Professionnelles
P. Messner Pellenc, C. Robert
P. Messner Pellenc, C. Robert Déclaration de Relations Professionnelles Disclosure Statement of Financial Interest J'ai actuellement, ou j'ai eu au cours des deux dernières années, une affiliation ou des
Hypertrophic Cardiomyopathy or «Athlete s Heart»
Hypertrophic Cardiomyopathy or «Athlete s Heart» S. GUERARD, J-R. CAIGNAULT, V. GRIFFET Desgenettes Military Hospital LYON Déclaration de Relations Professionnelles Disclosure Statement of Financial Interest
What is controversial in diagnostic imaging?
Controversies in the management of pulmonary hypertension What is controversial in diagnostic imaging? G. Derumeaux Lyon University Hospices Civils de Lyon France Déclaration de Relations Professionnelles
Insuffisance mitrale
Imagerie Multimodalité dans les Valvulopathies: De quoi avons nous besoin? Insuffisance mitrale Agnès Pasquet, MD, PhD Pôle de Recherche Cardiovasculaire Institut de Recherche Expérimentale et Clinique
MYOCARDITIS AND BIOMARKERS. Dr C. Guenancia Service de Cardiologie CHU Dijon
MYOCARDITIS AND BIOMARKERS Dr C. Guenancia Service de Cardiologie CHU Dijon Déclaration de Relations Professionnelles Disclosure Statement of Financial Interest J'ʹai actuellement, ou j'ʹai eu au cours
Continuous and noninvasive arterial blood pressure monitoring
Continuous and noninvasive arterial blood pressure monitoring Pr. Jean-Luc Fellahi fellahi-jl@chu-caen.fr Pôle Réanimations-Anesthésie-SAMU, CHU de Caen UFR de Médecine, EA4650, Université de Caen Basse-Normandie
Return to Work (RTW) after Acute Coronary Syndrom (ACS) SFC
+ Return to Work (RTW) after Acute Coronary Syndrom (ACS) SFC - 2016 No Conflict of interest for this subject Dany Michel Marcadet Paris Déclaration de Relations Professionnelles Disclosure Statement of
Left Ventricular Assist Device and Exercise
Left Ventricular Assist Device and Exercise Marie Christine Iliou Réadaptation cardiaque et prévention secondaire Hôpital Corentin Celton- HUPO Issy les Moulineaux Déclaration de Relations Professionnelles
Cancer Associated Thrombosis Approach to VTE recurrence
Cancer Associated Thrombosis Approach to VTE recurrence http://anticoag-pass-s2d.fr/ Isabelle Mahé Hôpital Louis Mourier Service de Médecine Interne APHP-Université Paris 7 EA REMES 7334-UMR 1140 France
Session: EBC s position on dedicated devices. Pro
Session: EBC s position on dedicated devices Pro Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive Cardiology Dept., Central Hospital of the
Role of Balloons and Stents in Congenital Heart Disease
Role of Balloons and Stents in Congenital Heart Disease Rui Anjos Lisbon, Portugal No conflict of interest Balloon dilatation in Congenital Heart Disease Balloons in CHD Initially used in the 80s Learning
Lessons for technique and stent choice
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Session: What are the requirements for using a stent in a bifurcation? Lessons for technique and stent choice October 12 th : 16:45 17:50 Goran
Progress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
COMPLEX CASES: LEFT MAIN
COMPLEX CASES: LEFT MAIN Resolute Onyx DES Together are trademarks of Medtronic. * Third-party brands are trademarks of For distribution only in markets where the Resolute Onyx coronary stent has been
ENDOVASCULAR REPAIR OF COMPLEX EXTRA-CRANIAL SUPRA-AORTIC ANEURYSMS
ENDOVASCULAR REPAIR OF COMPLEX EXTRA-CRANIAL SUPRA-AORTIC ANEURYSMS Deep Chandh Raja, MD DM DNB Fellow in Interventional Cardiology, The Madras Medical Mission, India Primary Operator: Dr George Joseph,
3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial
3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial William F. Fearon, MD, Takeshi Nishi, MD, Bernard De Bruyne, MD, PhD, Derek
Ultimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
Longitudinal stent distortion in clinical practice. How common is the problem and does stent design matter?
EXPERT OPINION P A Haworth Longitudinal stent distortion in clinical practice. How common is the problem and does stent design matter? M W I Webster F De Vroey T Watson J T Stewart P N Ruygrok J A Ormiston
CoA Stenting Alexandria Experience
CoA Stenting Alexandria Experience By Hani Mahmoud Adel, M.D Alexandria University 2/27/2017 CE 2017 Cairo 1 Coarctation of the aorta is the eighth most common form of congenital heart disease & accounts
Will Bioresorbable Scaffolds Change How We Think About Left Main PCI?
TCT 2014 13 Sep 2014-17 Sep 2014, Washington, DC - U.S.A Will Bioresorbable Scaffolds Change How We Think About Left Main PCI? Robert-Jan van Geuns, MD, PhD Professor of Interventional Cardiology, Thoraxcenter,
Branch Pulmonary Artery Stenosis Long-term Outcomes of Endovascular Stenting
Branch Pulmonary Artery Stenosis Long-term Outcomes of Endovascular Stenting Lee Benson MD Professor Pediatrics (Cardiology) Director, Cardiac Diagnostic & Interventional Unit The Hospital for Sick Children
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)
7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET) Hiroki Shiomi, MD Kyoto University Graduate School of Medicine
Post PCI functional testing and imaging: case based lessons from FFR React
Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest
Directional Atherectomy and Gender Outcomes in DEFINTIVE LE
Directional Atherectomy and Gender Outcomes in DEFINTIVE LE Lawrence A. Garcia MD, on behalf of the DEFINITIVE LE Investigators Chief, Section Interventional Cardiology St. Elizabeth s Medical Center,
Jose Mª de la Torre Hernandez, MD, PhD, FESC. Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander. SPAIN
Validation and application of IVUS-MLA in LMCA disease Jose Mª de la Torre Hernandez, MD, PhD, FESC Interventional Cardiology Dpt Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla Santander.
Stent Longitudinal Integrity
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 12, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.11.002 EXPEDITED
Optimal Techniques for Obtaining Large Caliber Arterial Access
Optimal Techniques for Obtaining Large Caliber Arterial Access Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 11 October 2014 Disclosure Statement
IVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
Pitfalls in the evaluation of carotid artery stenosis. Serge Kownator «Centre Cardiologique et Vasculaire» Thionville, Fr
Pitfalls in the evaluation of carotid artery stenosis Serge Kownator «Centre Cardiologique et Vasculaire» Thionville, Fr Disclosure Statement of Financial Interest I currently have, or have had over the
Longitudinal compression of the cobalt-chromium. everolimus-eluting stent during Percutaneous Coronary
Longitudinal compression of the cobalt-chromium everolimus-eluting stent during Percutaneous Coronary Implantation: The first report of accordion effect in Xience prime family in vivo LI CG 1, Dai YX 1,
Nicolas W Shammas, MD, MS
Rota%onal and Aspira%on Atherectomy in Trea%ng in- Stent Restenosis of Femoropopliteal Arteries: Final Results of the JETSTREAM- ISR Feasibility Study Nicolas W Shammas, MD, MS President and Research Director,
2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil
COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde
Resolute Integrity. Independent Conformability Assessment
Resolute Integrity Independent Conformability Assessment Stent Conformability and its Clinical Importance Immediate post-deployment stent geometry determines neointimal thickness independently of arterial
DISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University
DISRUPT CAD A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in heavily calcified coronary lesions Todd J. Brinton, MD Clinical Associate Professor of
Balloon Expandable Covered Stents. Suddenly a Crowded Space
Novel Balloon Expandable Covered Stents for Aorto-iliac Occlusive Disease: New Trial Data makes for an Interesting Balloon Expandable Covered Stents Comparison in Aorto-iliac Occlusive Disease: Andrew
Expanding to every demand: The GORE VIABAHN VBX Stent Graft
Expanding to every demand: The GORE VIABAHN VBX Stent Graft GORE, VIABAHN, and designs are trademarks of W. L. Gore & Associates. 2017 W. L. Gore & Associates, Inc. Program Faculty Martin Austermann, MD
LM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
Optical Coherence Tomography
Optical Coherence Tomography Disclosure Information Demetrius Lopes MD The following relationships exist related to this presentation: University Grant/Research Support: Rush University Industry Grant
The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
Patterns of Restenosis: A Core Lab-driven Assessment of SFA Restenosis and a Potential Shift to Unify Various Trials Lawrence A. Garcia, MD St.
Patterns of Restenosis: A Core Lab-driven Assessment of SFA Restenosis and a Potential Shift to Unify Various Trials Lawrence A. Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement
Combine the best of both worlds
S c i e n c e B a s e d E v o l u t i o n s l e a d t o R e v o l u t i o n a r y S o l u t i o n s PIONEER CoCr STENT ON DEB Combine the best of both worlds A next step in cardiovascular treatment should
Continuing Cardiology Education
Continuing Cardiology Education Stent selection for percutaneous coronary intervention P. D. Williams* & M. Awan James Cook University Hospital, Middlesbrough, United Kingdom Keywords Coronary artery disease,
XIENCE Sierra INTRODUCING
INTRODUCING Sierra With the safety you ve always relied on and the deliverability you ve always wanted, choosing the right stent is now an easier decision. START 2017 Abbott. All rights reserved. AP2944678-OUS
Selection and Use of Basic Equipment : Guiding Catheters, Wires and Balloons
SCAI Interventional Cardiology Fall Fellows Course 2014 Selection and Use of Basic Equipment : Guiding Catheters, Wires and Balloons December 7, 2014 8:30 am John S. Douglas Jr, MD Professor of Medicine
Coroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems
Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative
Measurement of Mechanical Properties of Coronary Stents according to the European Standard pren
February 1999 45 Measurement of Mechanical Properties of Coronary Stents according to the European Standard pren 12006-3 W. SCHMIDT, P. BEHRENS, D. BEHREND, K.-P. SCHMITZ Institute for Biomedical Engineering,
Longitudinal distortion of coronary stent in the Left Main Stem: A cautionary tale
Longitudinal distortion of coronary stent in the Left Main Stem: A cautionary tale Authors: 1.Ahmad Syadi Mahmood Zuhdi a Senior Lecturer in Cardiology syadizuhdi@yahoo.co.uk 2.Muhammad Dzafir Ismail a
The latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
When Outcomes Matter, Design Matters
to receive our latest news and key activities. Cordis S.M.A.R.T. Self-Expanding Nitinol Lower Extremity Solutions When Outcomes Matter, Design Matters For superficial femoral artery (SFA) and iliac lesions.
Algorithm and Tools for the Uncrossable CTO
Algorithm and Tools for the Uncrossable CTO David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC
Venous stent experience in Arnsberg Michael K. W. Lichtenberg MD, FESC IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label
Mechanical Properties of the GORE TIGRIS Vascular Stent
Mechanical Properties of the GORE TIGRIS The nitinol frame makes it strong. The fluoropolymers make it flexible. Together, they make it unique. Purpose The association of target vessel restenosis with
Vascular V12. Covered Stent. The New Standard of Care
Vascular V12 Covered Stent The New Standard of Care Innovation Novel Thermo-Conformable Covered Stent 316L stainless steel stent completely encapsulated in a proprietary one piece eptfe film cast covering
Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
IMAGES. in PAEDIATRIC CARDIOLOGY
IMAGES in PAEDIATRIC CARDIOLOGY Images Paediatr Cardiol. 2003 Apr-Jun; 5(2): 25 41. PMCID: PMC3232539 Balloon expandable stents for coarctation of the aorta: review of current status and technical considerations
Goal: Optimal Stent Deployment
Ground breaking, Life changing Goal: Optimal Stent Deployment Ground breaking, Life changing Cordis Corporation has no independent knowledge concerning the information contained in these presentations.
Affiliation/Financial Relationship Grant/ Research Support: Major Stock Shareholder/Equity Interest: Royalty Income: Ownership/Founder: Salary:
IMPLANTATION OF SAPIEN XT, TRANSFEMORAL TAPED CASE Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia TAVI Summit 9 th Aug 2013 Disclosure Statement
TAVI limitations for low risk patients
TAVI limitations for low risk patients Dr. T. Modine / P. Lancellotti MD, PhD, MBA CHRU de Lille, France Potential conflicts of interest Speaker's name: Thomas Modine I have the following potential conflicts
NC EMERGE TM PTCA Dilatation Catheter
LEARN MORE Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health
IMAGES. in PAEDIATRIC CARDIOLOGY
IMAGES in PAEDIATRIC CARDIOLOGY Images Paediatr Cardiol. 2005 Jan-Mar; 7(1): 12 17. PMCID: PMC3232568 Stent implantation for coarctation facilitated by the anterograde trans-septal approach N Sreeram and
Challenges of in-stent Restenosis. The Balloon Approach
Challenges of in-stent Restenosis The Balloon Approach Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III,
Echo Assessment Pre-TAVI
Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below Echocardiographic
Is a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
Coarctation of the aorta (CoA) accounts for
Stenting Coarctation of the Aorta Indications, techniques, and outcomes in treating native and recurrent CoA. By Thomas J. Forbes, MD, FACC, FSCAI, and Daisuke Kobayashi, MD Coarctation of the aorta (CoA)
CP STENT. Large Diameter, Balloon Expandable Stent
CP STENT Large, Expandable CP STENT OPTIONS 12mm to Expansion 26mm to Expansion CP Matrix (number of zigs) 1.6 2.2 2.8 3.4 3.9 4.5 5 5.5 6 12 14 15 16 18 20 22 24 26 28 30 CP Details: CP is composed of
In-stent Restenosis: the Achille's Heel of SFA Stenting
In-stent Restenosis: the Achille's Heel of SFA Stenting Yann Gouëffic, MD, PhD Department of Vascular Surgery University Hospital of Nantes, France «Unresolved problems of SFA stenting» In-stent restenosis
Magmaris: the impact of scaffold design and materials on reducing thrombogenicity
: the impact of scaffold design and materials on reducing thrombogenicity Michael Joner, MD Deutsches Herzzentrum München und Deutsches Zentrum für Herz-Kreislaufforschung e.v. Potential conflicts of interest
Clinical results of venous stents. Michael K. W. Lichtenberg MD, FESC
Clinical results of venous stents Michael K. W. Lichtenberg MD, FESC Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation
POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis
POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis Robert J. Gil 1,2, MD, PhD, FESC 1- Mossakowski Medical Research Centre, Polish Academy of Sciences 2- Invasive
Bench Insights into Bifurcation Stenting in the DES Era: An Update
Bench Insights into Bifurcation Stenting in the DES Era: An Update John Ormiston, Mark Webster, Peter Ruygrok, Jim Stewart, Douglas Scott, Duncan McNabb, Erin Currie, Monique Panther Mercy Hospital and
Stent Fracture and Longitudinal Compression on CT Angiography between the
2014 ASCI Stent Fracture and Longitudinal Compression on CT Angiography between the First- and New-Generation Drug-Eluting Stent Mi Sun Chung, Dong Hyun Yang,Young-Hak Kim, Jae-Hyung Roh, Joon-Won Kang,
Things we use in the catheter lab: Catheters, wires, balloons, stents, devices. Shakeel A Qureshi Evelina Children s Hospital London
Things we use in the catheter lab: Catheters, wires, balloons, stents, devices Shakeel A Qureshi Evelina Children s Hospital London SCAI Interventional Course, Las Vegas, December 2011 Disclosures Consultancy
Finally, the Control You Need to Deliver Accurate Treatment
Finally, the Control You Need to Deliver Accurate Treatment LIFESTREAM Covered Stent. has joined BD When you reach for a balloon expandable stent, you require accuracy. The LIFESTREAM Balloon Expandable
Investigation of metallic surface area of coronary stents
Investigation of metallic surface area of coronary stents Dóra KÁROLY 1, Miksa KOVÁCS 1, Andrew Attila TERDIK 1, Eszter BOGNÁR 1,2 1 Department of Materials Science and Engineering, Faculty of Mechanical
Evaluation of Stent Performances using FEA considering a Realistic Balloon Expansion
Evaluation of Stent Performances using FEA considering a Realistic Balloon Expansion Won-Pil Park, Seung-Kwan Cho, Jai-Young Ko, Anders Kristensson, S.T.S. Al-Hassani, Han-Sung Kim, and Dohyung Lim Abstract
Bench test : Is it still useful? Do we need standardization?
How to evaluate stents and techniques for bifurcation stenting? Bench test : Is it still useful? Do we need standardization? Yoshinobu Murasato MD, PhD Dept. of Cardiovascular Medicine, New Yukuhashi Hospital
Issam D. Moussa, MD. Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL
Carotid Technologies and Protection Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, FL Disclosure Statement
2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.
Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS, MD St Vincent s Hospital, Sydney On behalf of the Tendyne
Consensus so far and what we will be focusiong on this time
Consensus so far and what we will be focusiong on this time The 6 th European Bifurcation Club Meeting Budapest October 22-23 2010 Jens Flensted Lassen, MD, PH.D., FESC. Department of Cardiology B Skejby
ENDOVASCULAR FEMORAL STENTS CAN WE RELY ON LONG-TERM FRIENDSHIP?
ENDOVASCULAR FEMORAL STENTS CAN WE RELY ON LONG-TERM FRIENDSHIP? MEET 2007 MULTIDISCIPLINARY EUROPEAN ENDOVASCULAR THERAPY COURSE CANNES Emad A Hussein ; MD Vascular Surgery Department Ain Shams University
Current Status of Abdominal Aortic Stent Grafts. John R. Laird Professor of Medicine Director of the Vascular Center UC Davis Medical Center
Current Status of Abdominal Aortic Stent Grafts John R. Laird Professor of Medicine Director of the Vascular Center UC Davis Medical Center Autumn Greetings Disclosure Statement of Financial Interest Within
A Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression
Jikeikai Med J 2016 ; 63 : 71-6 Case Report A Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression Haruka Kimura, Tetsuya Ishikawa,
Management of Bleeding and Hemolysis. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Professor of
Management of Bleeding and Hemolysis Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Professor of Medicine @DrMauricioCohen Disclosure Statement of Financial Interest Within the
Bifurcations Bad Krozingen I
Bifurcations Bad Krozingen I Clinical outcome 5 years after routine T-Stenting versus provisional T-stenting in the treatment of de novo coronary bifurcation lesions using sirolimus-eluting stents M. Ferenc
Absorbable Scaffolds the Future of Coronary Interventions?
Absorbable Scaffolds the Future of Coronary Interventions? Brock Cookman, DO, MSA Interventional Cardiology Mercy Heart and Vascular Institute April 8, 2017 None Disclosures Objectives History of cardiac
Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
Impact of overxpan/on strategies: Insights from bench Tes/ng
Impact of overxpan/on strategies: Insights from bench Tes/ng Robert- Jan van Geuns, MD, PhD Professor of Interven7onal Cardiology, Thoraxcenter, Erasmus Medical Center, RoCerdam, the Netherlands CCI 2013:
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
Bifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have